NIH Study Suggests That 200 mg Is The Optimal Daily Dose of Vitamin C

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 5
Volume 5
Issue 5

BETHESDA, Md--Although only 10 mg/day of vitamin C is enough to prevent deficiency, the optimal daily intake is probably 200 mg, according to results of a new NIH-sponsored study. The current Recommended Dietary Allowance (RDA) is 60 mg.

BETHESDA, Md--Although only 10 mg/day of vitamin C is enough toprevent deficiency, the optimal daily intake is probably 200 mg,according to results of a new NIH-sponsored study. The currentRecommended Dietary Allowance (RDA) is 60 mg.

In this study, vitamin C was given in various amounts to sevenhealthy young male volunteers who lived in a hospital ward forthe duration of the study so that intake could be strictly controlled.The NIH researchers, led by Dr. Mark Levine, found that the 200mg level was best absorbed by the body; absorption levels fellas the dose was raised above 200 mg.

Daily doses higher than 400 mg offer no additional value, Dr.Levine said, since, at that level, a large amount of the doseis excreted from the body. The research also suggests that veryhigh doses could be dangerous: At 1,000 mg/day, the urine wasfound to contain oxalate, a breakdown product of the vitamin thatcould lead to kidney stone formation in some people.

Recent Videos
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Genetic backgrounds and ancestry may hold clues for better understanding pancreatic cancer, which may subsequently mitigate different disparities.
Factors like genetic mutations and smoking may represent red flags in pancreatic cancer detection, said Jose G. Trevino, II, MD, FACS.
Thomas Hope, MD, believes that an NRC initiative to update infiltration guidelines may organically address concerns that H.R. 2541 outlines.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
4 experts are featured in this series.
4 experts are featured in this series.
Thomas Hope, MD, had not observed an adverse effect attributable to an infiltration across more than a decade of administering nuclear agents at UCSF.
Numerous clinical trials vindicating the addition of immunotherapy to first-line chemotherapy in SCLC have emerged over the last several years.
Two experts are featured in this series.
Related Content